Edward Brewer, MD
Family Medicine · Whitfield, MSNPI 1831106418
Payments from drug & device makers
Across 50 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$195
- Avanir Pharmaceuticals, Inc.$132
- Neurocrine Biosciences, Inc.$127
- Lundbeck LLC$100
- Otsuka America Pharmaceutical, Inc.$88
- Alkermes, Inc.$81
- plus $250 from 9 others
What the payments were for
- Food & beverage$973100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 10 | $195 |
| Avanir Pharmaceuticals, Inc. | 8 | $132 |
| Neurocrine Biosciences, Inc. | 7 | $127 |
| Lundbeck LLC | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $88 |
| Alkermes, Inc. | 4 | $81 |
| Johnson & Johnson | 3 | $61 |
| Greenwich Biosciences, Inc. | 2 | $42 |
| Livanova USA, Inc. | 2 | $37 |
| AbbVie | 1 | $21 |
| Indivior Inc. | 1 | $20 |
| UCB, Inc. | 1 | $19 |
| Bioxcel Therapeutics, Inc. | 1 | $18 |
| Stryker | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
How this compares
$973 in reported general payments places this provider in the 55th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TivicayDolutegravir Sodium | 41 | $46,039 |
| EpidiolexCannabidiol (Cbd) | 12 | $36,637 |
| DescovyEmtricitabine/Tenofov Alafenam | 18 | $19,698 |
| EliquisApixaban | 56 | $16,227 |
| JanuviaSitagliptin Phosphate | 44 | $12,504 |
| Abacavir-LamivudineAbacavir Sulfate/Lamivudine | 11 | $5,664 |
| Risperidone OdtRisperidone | 23 | $5,624 |
| Divalproex Sodium | 146 | $4,515 |
| Aripiprazole | 82 | $3,623 |
| Ketoconazole | 33 | $3,147 |
| Lacosamide | 36 | $2,887 |
| Clonidine | 20 | $2,786 |
| Felbamate | 11 | $2,713 |
| Valproic AcidValproic Acid (As Sodium Salt) | 53 | $2,543 |
| Pravastatin Sodium | 212 | $2,271 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Whitfield
- Karen WhitneyWhitfield$117K
- Paul MatherneGulfport$14.4M
- Timothy QuinnRidgeland$8M
- Sean KerbyGulfport$6.6M
- Rambod RouhbakhshHattiesburg$6M
- Randall HulingOlive Branch$4.6M
- Demetri MarshallPort Gibson$3M
- Alexander OsowaJackson$2.2M
- Russell CarlisleWesson$1.6M
- Kristi TrimmRidgeland$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.